Skip to main content
Top
Published in: Diabetologia 8/2005

01-08-2005 | Article

Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice

Authors: M. Ito, H. Bujo, K. Takahashi, T. Arai, I. Tanaka, Y. Saito

Published in: Diabetologia | Issue 8/2005

Login to get access

Abstract

Aim/hypothesis

In type 1 diabetic patients, basal insulin supplementation plays a central role in tight glycaemic control. Therefore, safe and steady supplementation of basal insulin is strongly desirable, despite the need for multiple injections. The aim of this study was to investigate a procedure for supplementation using genetically engineered, primary-cultured adipocytes in diabetic mice.

Methods

Furin-cleavable human proinsulin cDNA was transferred into murine primary-cultured adipocytes using a retroviral vector. The cells were implanted subcutaneously into streptozotocin-induced diabetic mice.

Results

The transfected cells secreted substantial amounts of mature insulin, as well as C-peptide, into conditioned medium. Syngeneic implantation of the cells significantly improved hyperglycaemia and blood HbA1c concentrations in a manner that was dependent on cell number, without causing hypoglycaemia. The plasma insulin concentration was dependent on the implanted cell number, and the systemic effect of the circulating insulin was confirmed by marked improvement of body weight reduction and liver glycogen content. Additionally, surgical resection of the implants, in which the insulin secretion was immunologically confirmed after transplantation, diminished the glucose-lowering effect, suggesting that in vivo expression could be eliminated if necessary.

Conclusions/interpretation

These results indicate that the autotransplantation of functionalised adipocytes may lead to a clinical application in the treatment of diabetes.
Literature
1.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986 The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
2.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853 UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
3.
go back to reference The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. Diabetes 46:271–286 The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. Diabetes 46:271–286
5.
go back to reference Bailey CJ, Davies EL, Docherty K (1999) Prospects for insulin delivery by ex-vivo somatic cell gene therapy. J Mol Med 77:244–249 Bailey CJ, Davies EL, Docherty K (1999) Prospects for insulin delivery by ex-vivo somatic cell gene therapy. J Mol Med 77:244–249
6.
go back to reference Shimomura I, Funahashi T, Takahashi M et al (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800–803CrossRefPubMed Shimomura I, Funahashi T, Takahashi M et al (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800–803CrossRefPubMed
7.
go back to reference Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed
8.
go back to reference Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946CrossRefPubMed Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946CrossRefPubMed
9.
go back to reference Shibasaki M, Takahashi K, Itou T et al (2002) Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia 45:518–526CrossRefPubMed Shibasaki M, Takahashi K, Itou T et al (2002) Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia 45:518–526CrossRefPubMed
10.
go back to reference Sugihara H, Yonemitsu N, Miyabara S, Yun K (1986) Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties. Differentiation 31:42–49PubMed Sugihara H, Yonemitsu N, Miyabara S, Yun K (1986) Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties. Differentiation 31:42–49PubMed
11.
go back to reference Groskreutz DJ, Sliwkowski MX, Gorman CM (1994) Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem 269:6241–6245PubMed Groskreutz DJ, Sliwkowski MX, Gorman CM (1994) Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem 269:6241–6245PubMed
12.
go back to reference Arai T, Takada M, Ui M, Iba H (1999) Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts. Virology 260:109–115CrossRefPubMed Arai T, Takada M, Ui M, Iba H (1999) Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts. Virology 260:109–115CrossRefPubMed
13.
go back to reference Muzzin P, Eisensmith RC, Copeland KC, Woo SL (1997) Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats. Mol Endocrinol 11:833–837 Muzzin P, Eisensmith RC, Copeland KC, Woo SL (1997) Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats. Mol Endocrinol 11:833–837
14.
go back to reference Dong H, Morral N, McEvoy R, Meseck M, Thung SN, Woo SL (2001) Hepatic insulin expression improves glycemic control in type 1 diabetic rats. Diabetes Res Clin Pract 52:153–163CrossRefPubMed Dong H, Morral N, McEvoy R, Meseck M, Thung SN, Woo SL (2001) Hepatic insulin expression improves glycemic control in type 1 diabetic rats. Diabetes Res Clin Pract 52:153–163CrossRefPubMed
15.
go back to reference Vogt PA (1989) Abdominal lipoplasty technique. Clin Plast Surg 16:279–288PubMed Vogt PA (1989) Abdominal lipoplasty technique. Clin Plast Surg 16:279–288PubMed
17.
go back to reference Zhang HH, Kumar S, Barnett AH, Eggo MC (2000) Ceiling culture of mature human adipocytes: use in studies of adipocyte functions. J Endocrinol 164:119–128CrossRefPubMed Zhang HH, Kumar S, Barnett AH, Eggo MC (2000) Ceiling culture of mature human adipocytes: use in studies of adipocyte functions. J Endocrinol 164:119–128CrossRefPubMed
18.
go back to reference Madsbad S, Alberti KG, Binder C et al (1979) Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 2:1257–1259PubMed Madsbad S, Alberti KG, Binder C et al (1979) Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 2:1257–1259PubMed
19.
go back to reference Johansson BL, Kernell A, Sjoberg S, Wahren J (1993) Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 77:976–981 Johansson BL, Kernell A, Sjoberg S, Wahren J (1993) Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 77:976–981
20.
go back to reference Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563–566CrossRefPubMed Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563–566CrossRefPubMed
21.
go back to reference Sjoquist M, Huang W, Johansson BL (1998) Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 54:758–764CrossRefPubMed Sjoquist M, Huang W, Johansson BL (1998) Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 54:758–764CrossRefPubMed
22.
go back to reference Pieber TR, Eugene-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European study group of HOE 901 in type 1 diabetes. Diabetes Care 23:157–162PubMed Pieber TR, Eugene-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European study group of HOE 901 in type 1 diabetes. Diabetes Care 23:157–162PubMed
23.
go back to reference Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636PubMed Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636PubMed
24.
go back to reference Kawakami Y, Yamaoka T, Hirochika R, Yamashita K, Itakura M, Nakauchi H (1992) Somatic gene therapy for diabetes with an immunological safety system for complete removal of transplanted cells. Diabetes 41:956–961PubMed Kawakami Y, Yamaoka T, Hirochika R, Yamashita K, Itakura M, Nakauchi H (1992) Somatic gene therapy for diabetes with an immunological safety system for complete removal of transplanted cells. Diabetes 41:956–961PubMed
25.
go back to reference Falqui L, Martinenghi S, Severini GM et al (1999) Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Hum Gene Ther 10:1753–1762CrossRefPubMed Falqui L, Martinenghi S, Severini GM et al (1999) Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Hum Gene Ther 10:1753–1762CrossRefPubMed
26.
go back to reference Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419CrossRefPubMed Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419CrossRefPubMed
Metadata
Title
Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice
Authors
M. Ito
H. Bujo
K. Takahashi
T. Arai
I. Tanaka
Y. Saito
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1825-0

Other articles of this Issue 8/2005

Diabetologia 8/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.